戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 phenol (APAP, or paracetamol), a hepatotoxic analgesic drug.
2 its, and therefore might not be an effective analgesic drug.
3 nd possibly a promising candidate as a novel analgesic drug.
4 d possibly a promising candidate for a novel analgesic drug.
5 the most commonly used anti-inflammatory and analgesic drug.
6 gical antagonist will produce a new class of analgesic drug.
7 rgets for antiepileptic, antiarrhythmic, and analgesic drugs.
8 ntipyretic and one of the most commonly used analgesic drugs.
9 id (aspirin), and paracetamol-caffeine-based analgesic drugs.
10 suggests a new avenue for the development of analgesic drugs.
11  foundation for investigating new classes of analgesic drugs.
12 rders and provide an approach for developing analgesic drugs.
13 5/p35 may be a target for the development of analgesic drugs.
14 and mediate the effects of the most powerful analgesic drugs.
15 d therefore increase the clinical utility of analgesic drugs.
16 ful in the assessment of peripherally acting analgesic drugs.
17 onal signal transduction mechanisms for some analgesic drugs.
18 ression of pain, and in the action of opiate analgesic drugs.
19 for developing future resting-state-targeted analgesic drugs.
20 btype-selective muscarinic agonists as novel analgesic drugs.
21 gets of native opioid peptides and addictive analgesic drugs.
22 pairment, and pain relief obtained by taking analgesic drugs.
23 e to the acute and chronic actions of opioid analgesic drugs.
24 sts, as well as P2X antagonists as potential analgesic drugs.
25 e sorely needed to reduce reliance on opioid analgesic drugs.
26 e of psychotropic (16.4% vs 42.4%) and other analgesic drugs (22.9% vs 47.3%) prior to opioid initiat
27 minimizing the predilection for sedative and analgesic drug accumulation with prolongation of effect
28 nd hospital stays, and doses of sedative and analgesic drugs administered were recorded.
29 d to a wealth of molecular targets for novel analgesic drugs and many clinical drug trials.
30 ) 1.7, a major target for the development of analgesic drugs and more generally for the study of pain
31                          New developments in analgesic drugs and techniques are being applied to the
32 strated a link between the administration of analgesic drugs and the reduction of empathy levels in h
33 ugh to require increased use of sedative and analgesic drugs, and is among the events that predict cl
34 gate, provides little support for the use of analgesic drugs as chemoprevention for this disease.
35  (APAP) is widely used as an antifebrile and analgesic drug at recommended doses, whereas an overdose
36 ASC alone (treatment could include steroids, analgesic drugs, bronchodilators, palliative radiotherap
37 , and non-steroidal anti-inflammatory drugs) analgesic drugs can markedly enhance pain relief in the
38           Acetaminophen (AAP), a widely used analgesic drug, can damage various organs when taken in
39 t that is also a short acting anesthetic and analgesic drug, can produce analgesia and decrease morph
40     Overdose of acetaminophen, a widely used analgesic drug, can result in severe hepatotoxicity and
41                       Salicylamide (SAL), an analgesic drug, caused a potent and long-lasting inhibit
42               At least 2 different nonopioid analgesic drug classes (cyclooxygenase inhibitors, aceta
43         Importantly, the number of nonopioid analgesic drug classes administered during surgery predi
44 rgent, sugar, and paracetamol-caffeine-based analgesic drugs), common ions, and other explosives were
45 and modulation reveals potential targets for analgesic drug development and new therapeutic opportuni
46 d wiring patterns that provide clues for new analgesic drug development strategies.
47 ss, the chances of success could increase if analgesic drug development strategy changed.
48 r channel function, potentially facilitating analgesic drug development studies.
49  a key target for the spicy taste sensor and analgesic drug development.
50 sodium channel is therefore a key target for analgesic drug development.
51 patients but may also reveal new targets for analgesic drug development.
52 d receptor (DOR) is an attractive target for analgesic drug development.
53 ive research could be designed to accelerate analgesic drug development.
54  may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and rel
55 e the challenges associated with the current analgesic drug discovery model and review evidence in fa
56 gation to support the use of aboBoNT-A as an analgesic drug for post-surgical pain, is warranted.
57 r testing not only antiinflammatory but also analgesic drugs for potential use in RA, and highlights
58 58.4% of these patients received antipyretic analgesic drugs for symptom management.
59 st significance in the development of potent analgesic drugs for the treatment of severe pain.
60 a-1, the receptor for the anti-epileptic and analgesic drug gabapentin.
61 itization are known, inadequacies of current analgesic drugs have prompted a search for additional ta
62 arch is needed to investigate the effects of analgesic drugs in high frequency users.
63                       The attrition of novel analgesic drugs in the clinic can be attributed in the m
64 act of laboratory procedures and efficacy of analgesic drugs in the model species, the zebrafish.
65 lly online, multichannel HPLEC separation of analgesic drugs (including acetaminophen, ibuprofen, and
66 essential for the action of a novel class of analgesic drugs, including 3-iodobenzoyl-6beta-naltrexam
67                       Prescription of opioid analgesic drugs is a major contributing factor to the cu
68                        Delivery of promising analgesic drugs is often impeded by the perineurium, whi
69 orbidities and use of psychotropic and other analgesic drugs, likely reflecting a higher prevalence o
70 eported that the short-acting anesthetic and analgesic drug midazolam can produce analgesia and decre
71 o, 2.9; p < 0.001), lower amount of sedative-analgesic drugs (odds ratio, 1.9; p = 0.03), higher vaso
72                            Bone pain, use of analgesic drugs, performance status, and quality of life
73           Commonly used opioid and nonopioid analgesic drugs produce adverse effects and are of limit
74 nslational pain research but also in in vivo analgesic drug screening and validation, without the nee
75 t reviews have suggested that newly designed analgesic drugs should incorporate multiple targets.
76 th bone metastases, in part because existing analgesic drugs show only limited efficacy in many patie
77                       Repeated use of opiate analgesic drugs such as morphine for the relief of chron
78 lesser degree than opioid peptides and other analgesic drugs, such as methadone, and previous studies
79 rget for the development of a novel class of analgesic drugs, suggesting that activation of TREK-1 co
80 e all been shown to be potentially selective analgesic drug targets in some animal pain models.
81 egabalin with conventional antiepileptic and analgesic drug targets is likely to be modest, at best,
82 into human pain mechanisms and suggested new analgesic drug targets.
83 egulation mediating type-specific effects of analgesic drugs that activate more than one type of opio
84  required, 1 which includes a combination of analgesic drug therapy, radiation therapy, hormonal ther
85  deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of l
86 nses of geriatric patients to anesthetic and analgesic drugs used during ambulatory surgery.
87      Here, we develop a strategy to discover analgesic drugs via structure-based virtual screening ba
88 NCE STATEMENT Acetaminophen is a widely used analgesic drug with multiple but only incompletely under
89 esign, we also tested whether pregabalin, an analgesic drug with proven efficacy on the dorsal horn,
90 being replaced by a combination of nonopioid analgesic drugs with diverse modes of action as part of
91 uld provide an approach toward the design of analgesic drugs with reduced side effects.
92                           Opioids are potent analgesic drugs with widespread cortical, subcortical, a